DSM will also sell its LldPE Compact Solution Technology to Borealis.
Subject to customary approvals and notifications, the transaction is expected to close in Q1 2013.
In 2012, DEXPlastomers anticipates sales of approximately €180m. Currently, 95 DSM employees are in the scope of the transaction.
For DSM, a sale of DEXPlastomers is in line with its long-term focus of being a Life Sciences and Materials Sciences company, active in health, nutrition and materials. DSM’s 50% participation in DEXPlastomers is reported under Corporate Activities in DSM’s accounts.
Source: DSM
© FoodBev Media Ltd 2024